News FDA rejects J&J's sirukumab RA drug The FDA has rejected Johnson & Johnson’s next-generation rheumatoid arthritis drug, sirukumab, calling for more clinical data to evaluate its safety.
News Pfizer sues J&J, alleging it blocked access to Remicade bios... J&J used anticompetitive tactics to prevent use of cheaper Inflectra
News Janssen axes hep C development with Achillion Johnson & Johnson has ended a collaboration with US biotech Achillion to develop hepatitis C drugs, sending the US biotech firm's shares plummeting.
News Mundipharma to distribute J&J diabetes drugs in Europe European pharma group Mundipharma has struck a deal with Janssen for two primary care diabetes drugs, Invokana and Vokanamet, in selected European countries.
News J&J speaks out as old drug included in lethal injection State of Florida to use untried cocktail in execution of Mark Asay
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
